In 2020, the prospect of shipping
perishable COVID-19 vaccines around
the globe pushed the pharmaceutical
cold chain into the spotlight. The
requirement for trustworthy, climatecontrolled transportation and storage
at an unprecedented scale and reach
called attention to the complexities
surrounding the worldwide distribution
of temperature-sensitive medicines and
clinical trial materials (CTMs).
At the same time, investigations in
modalities such as cell and gene
therapies continue to proliferate, with
related complex supply chain needs.
As personalised medicines and other
types of clinical trials have grown
more global and patient-centric, the
industry demand for fast-turnaround
and/or direct-to-patient (DTP) and
direct-from-patient (DFP) capabilities
has increased sharply. The capacity
and expertise to manage a multitude
of complicated variables from the
expiration of sensitive medicines,
to special handling requirements
in transit, to global regulatory
considerations is crucial to support a
broad demographic of global patients
as they participate in a wide range of
clinical trials from home.
Patient wellbeing and clinical trial
success both hinge on efficient,
compliant CTM distribution and
administration. When combined
with robust infrastructure, global
experience, and innovative packaging
solutions, the storage of supplies
and clinical drug products close to
patients, when appropriate, can be
a key strategy. Only a clinical trial
supply chain partner that offers
expert global regulatory and trade
compliance proficiency and that
transports shipments in a secure,
closed-loop environment while
meeting all GDP/GMP/GCP standards
can successfully address the complex
demands of the patient-centric supply
chain – and enable sponsors and
CROs to keep clinical trials moving
forward with on-time delivery of
lifesaving treatments.
|
